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Abstract 
Background: Insecticide‑treated bed nets (ITNs) are now the main tool for malaria prevention in endemic areas. 
Synthetic pyrethroids are the only group of insecticides recommended by the World Health Organization for the use 
on ITNs. There are only few studies which have specifically investigated potential adverse effects of frequent exposure 
to ITNs in the vulnerable group of young infants and their mothers.
Methods: This study was nested into a large randomized controlled ITN effectiveness trial. Ninety newborns and 
their mothers were selected from the study population for participation. Together with their mothers they were pro‑
tected with ITNs from birth (group A, n = 45) or from age 6 months (group B, n = 45) and followed up for 18 weeks 
(daily visits in the first 4 weeks, weekly visits thereafter). Potential side effects related to synthetic pyrethroids (del‑
tamethrin) exposure were systematically investigated by trained field staff. The frequency and duration of respective 
symptoms was compared between the two study groups.
Results: A total of 180 participants (90 mothers and 90 infants) were followed up over the study period without any 
loss to follow up. There were no significant differences in the frequency and duration of side effects between the two 
study groups, except that the frequency of headache was significantly higher in group A compared to group B moth‑
ers (p = 0.01).
Conclusions: The study provides further evidence for ITNs being sufficiently safe in children and even in newborns. 
The association with headache in mothers could be explained by them handling the ITNs more intensely or it could 
be a chance finding.
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Background
Although malaria control interventions have been sub-
stantially scaled up during the past decade malaria still 
accounts for an estimated 190 million clinical cases and 
584,000 deaths every year [1]. The majority of severe 
cases and deaths occur in sub-Saharan Africa (SSA), 
mainly in pregnant women and young children of remote 
rural areas [2]. Insecticide-treated bed nets (ITNs) are 
considered the most important tool for malaria preven-
tion in endemic areas and were found to be highly effec-
tive in reducing malaria morbidity and mortality in many 
different epidemiological settings [2, 3]. Therefore, scal-
ing up ITN coverage and usage by young children and 
pregnant women is among the major targets of the inter-
national efforts to roll back malaria [4–6].
Synthetic pyrethroid insecticides were mainly devel-
oped by the team of Michael Elliott at Rothamsted 
Research in the 1960s and 1970s [7]. Compared to nat-
ural pyrethrin, synthetic pyrethroids are much more 
stable and have, therefore, been widely used in agricul-
ture to control a variety of pests [8]. Investigations on 
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the potential of ITNs to control malaria started during 
the 1980s [2, 9]. However, decades later, synthetic pyre-
throids remain the only group of insecticides approved 
from the World Health Organization Pesticide Evaluation 
Scheme (WHOPES) to be used for treating mosquito 
nets [10]. This is because of the rapid knock-down effects 
and high insecticidal potency of pyrethroids, combined 
with their relative safety for human contact and domes-
tic handling [2, 10, 11]. Pyrethroids are evoking no major 
symptoms of poisoning if used with the recommended 
precautions; only mild and reversible paraesthesia has 
regularly been reported from persons having been in 
unprotected contact with the insecticide or with ITNs 
[12–14]. However, some debate on the safety of frequent 
exposure to low concentrations of pyrethroids continued, 
especially after evidence for an irreversible and cumula-
tive effect of pyrethroid on nerve tissue in animal models 
was published in 1984 [15, 16]. As a consequence, market 
withdrawal has even been considered in some developed 
countries until all adverse effects could be ruled out [17, 
18]. Moreover, occupational poisoning from pyrethroids 
among the people doing the spraying was reported from 
some countries like China [19–22]. However, only very 
little data are available on potential toxicity of frequent or 
long-term exposure to low-level pyrethroids among ITNs 
users in malaria endemic countries [14, 15, 23].
Among the ITN users, infants are considered biologi-
cally more vulnerable and thus likely more susceptible 
for insecticide side effects, which may be aggravated by 
oral exposure [24–26]. It has been observed that infants 
frequently suck and chew ITNs which may accumulate 
insecticide in their body. Moreover, young infants are 
likely more susceptible to the neurotoxic effects of syn-
thetic pyrethroids compared to older children [15, 16, 
26].
This study presents data which were prospectively col-
lected from a large randomized controlled trial (RCT) on 
the effects of deltamethrin among infant-mother-pairs in 
a malaria endemic area of rural Burkina Faso.
Methods
Study area
The trial took place in the rural research zone of the Cen-
tre de Recherche en Santé de Nouna (CRSN) in Nouna 
Health District (NHD), north-western Burkina Faso [27]. 
The Nouna area is a dry orchard savannah, populated 
mainly by subsistence farmers of various ethnic groups 
[28].
Malaria was holoendemic but highly seasonal in the 
study area; the rainy season lasts from July until Octo-
ber and the main transmission period is between July 
and December [29]. The number of infective bites per 
person per year-i.e. the Entomological Inoculation Rate 
(EIR)—varied between 100 and 1000 in the different 
study villages [30]. ITNs were not available in the study 
area until the start of this trial in the year 2000, but about 
one quarter of young children were usually protected 
with untreated bed nets in the study villages during rainy 
seasons [27]. Mothers regularly sleep with infants under 
the same bed net.
Study design and participants
This study was nested into a large randomized controlled 
effectiveness trial [27]. In brief, a total of 3387 neonates 
from all 41 villages of the rural CRSN study area were 
individually randomized to receive either ITN protection 
from birth (group A) or from 6 months of age (group B) 
until their fifths birthday. Malaria incidence and all-cause 
mortality were the primary endpoints.
A convenience sample of 90 neonates (45 group A, 45 
group B) and their mothers from five representative vil-
lages of the CRSN study area were selected for this sur-
vey. In these five villages, the first children recruited for 
the trial were subsequently included into this sub-study 
until the overall sample size was reached. Inclusion cri-
teria were recruitment within 2 weeks of birth, and being 
a permanent resident in the study villages. Recruitment 
was done by fieldworkers who were regularly informed 
about births by village informants during their twice-
weekly visits to the study villages [27].
First generation PermaNet™, a product of Vestergaard 
Frandsen Group in Denmark, was used during this trial 
[27]. These ITNs were family size rectangular green nets 
of 100 denier strength [31]. Study children and mothers 
were visited by village-based trained field staff daily in 
the first 4 weeks and then followed up weekly for another 
14 weeks, so the total follow-up period was 18 weeks. A 
questionnaire administered to the mothers during visits 
inquired about the presence and duration of side effects 
potentially caused by pyrethroids in both the mothers 
and the infants (e.g. pruritus,conjunctivitis,skin eruption, 
headache/dizziness, paresthesia). Field workers were 
trained to verify the reported symptoms through direct 
observation/examination if possible.
Data management and analysis
Data were cleaned and entered by the field staff of the 
trial in collaboration with the data management center of 
CRSN [27]. Data analysis based on the original database 
of the trial took place at the University of Heidelberg. 
The frequency of infants or mothers with specific symp-
toms (defined as at least one episode of respective side 
effects) and the duration of symptoms in days of potential 
side effects was compared for different follow up periods 
(the first week, the 2nd to the 4th weeks and the total 
18 weeks).
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Statistical analysis was performed with SAS software 
(version 9.2, 2015). Fisher’s Test was used to compare dif-
ferences in frequency of symptoms between group A and 
B according to the different follow up periods. Risk ratios 
with 95 % exact confidence intervals (CI) were calculated 
on the frequency of each side effect. The Wilcoxon Rank 
Sum Test was used to compare differences in the dura-
tion of the symptoms between group A and group B 
according to the different follow up periods. Significance 
was accepted at p ≤ 0.05.
Ethical aspects
The study protocol was approved by the Ethical Com-
mittee of the Heidelberg University Medical School and 
the local Ethical Committee in Nouna, Burkina Faso. 
Informed community consent was sought through expla-
nations and discussions during village meetings before 
the study was implemented. Oral informed consent from 
interviewees was a prerequisite for the interviews and the 
observations/examinations.
Results
All trial children of this sub-study were followed up 
from January, 2001 until April, 2002, without any loss 
to follow-up. The percentage of follow-up visits without 
records is around 10  % for the total follow-up period, 
with no significant differences between the two study 
groups.
Infants
The associations between pyrethroid exposure and the 
occurrence of the reported side effects are shown in 
Table  1. The most frequently mentioned symptoms of 
infants were rhinitis and cough. In addition, side effects, 
such as skin eruption diarrhoea, conjunctivitis, vomiting, 
anal fissure and others were reported; other (rare) symp-
toms include mycoses, ear pain, convulsion, open wound, 
inflammation, stomach ache and constipation. There 
were no significant differences in the frequency and dura-
tion of these symptoms between the two study groups 
during the overall follow up.
Mothers
The associations between pyrethroid exposure and 
reported side effects are shown in Table  2. In mothers, 
headache/dizziness and rhinitis were the most prominent 
symptoms, followed by skin eruption, pruritus, pares-
thesia, cough, conjunctivitis and other symptoms; other 
(rare) symptoms included stomachache, diarrhoea, open 
wound, ear pain, fatigue, kidney pain and thoracal pain. 
There were no significant differences in the frequency 
and duration of these symptoms between the two study 
groups during the overall follow up period, except that 
mothers of group A reported significant higher frequency 
of headache/dizziness compared to group B mothers 
(p = 0.01).
Discussion
This study reports the findings of an individually ran-
domized trial which specifically investigates the side 
effects of frequent exposure to low levels pyrethroids 
(deltamethrin) among ITNs users (both infants and 
mothers) in a highly endemic malaria area. The results 
for mothers are different from those for infants. While 
among the mothers there was a significantly increased 
risk of the symptom headache/dizziness in those hav-
ing been exposed to ITNs, no significant differences in 
the frequency and duration of potential side effects were 
observed among infants.
Acute toxicity of pyrethroids usually results from 
occupational use, such as unsafe spraying of the insecti-
cides (e.g. using higher concentration, longer exposure 
duration, spraying against the wind, or lack of personal 
protection) [10, 22] or unprotected treatment of large 
numbers of bed nets with the insecticide [32]. The onset 
of acute side effects varies from hours to a few days and 
depends on the way of absorption and dosage [19]. In this 
study, there were no symptoms attributed to ITN expo-
sure in infants, but headache/dizziness was attributed 
to ITN exposure in mothers during the first week. This 
is surprising, as animal experiments found neonatal rats 
being 4–17 times more vulnerable to the acute toxicity of 
pyrethroids than adult rats [33, 34].
Exposure by inhalation
Pyrethroids have a low vapour pressure, therefore, the 
contribution of inhalation for pyrethroids toxicity was 
considered to be largely negligible [14, 35]. However, 
if used in a confined space, concerns about inhalational 
exposure may still be justified [36]. This concern was not 
supported by the findings from this study. However, a 
higher frequency of cough was reported from ITN users 
in northern Ghana [37].
Rhinitis may also stem from inhalation exposure, 
affecting the nasal mucosa and causing irritation, and rhi-
nitis was found as a side effect to pyrethroid exposure in 
an animal model [38]. However, this has not been seen in 
this study.
Skin exposure
It has been reported that, compared to adults, infants 
absorbed relatively higher amounts of deltamethrin 
through skin contact when sleeping under an ITN [14]. 
In this study skin eruption occurred for longer periods 
in children not being exposed to ITNs, also this finding 
was not significant. It is well known that ITNs provide 
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a physical and a chemical barrier against a variety of 
household pests, e.g. spiders, fleas, ticks, carpenter ants, 
bees, cockroaches and bedbugs, which might cause skin 
infections [39].
It is surprising that such a protective effect of ITNs 
regarding skin related symptoms was not seen in moth-
ers of this study. In contrast, mothers exposed to ITNs 
reported (non-significantly) more days of skin symptoms 
including skin eruption, pruritus and paraesthesia, which 
supports findings from other research on this topic [20, 
40]. These symptoms are usually transient and reversible, 
and in particular paresthesia is regarded as an acceptable 
side effect during ITN usage [10].
Oral exposure
Oral exposure is likely to occur only in young children, 
not in their mothers. It has been speculated that infants 
are at risk of absorbing pyrethroids due to their sucking 
behaviour. In fact, it has been observed in this study that 
infants frequently take the ITN into their mouth. How-
ever, there was no difference between the study groups 
with regard to diarrhoea and vomiting. Interestingly, in 
this study, anal fissure was found to be more common in 
infants exposed to ITNs, also this finding did not reach 
statistical significance. Anal fissures occur frequently in 
infants, and constipation is considered the predominant 
cause [41]. Constipation has also been reported as a 
potential side-effect related to pesticide contact [42].
Systemic toxicity
Systemic toxicity may develop after intense dermal expo-
sure, inhalation or ingestion. Symptoms of systemic tox-
icity include headache/dizziness, convulsion, fatigue and 
vomiting. These symptoms were partly included into the 
category “other symptoms” in this study. There were no 
obvious indications for symptoms of systematic toxicity 
being associated with ITN exposure in this study. Only 
headache/dizziness was significantly more frequently 
reported in mothers exposed to ITNs compared to those 
not exposed during the first week. This finding is consist-
ent with reports from the literature [43–45].
It appears important to consider a variety of pyrethroid 
exposure possibilities of mothers. Besides sleeping under 
an ITN, mothers are also in charge of hanging it up, 
washing it and re-impregnating it. The bed nets of this 
trial were regularly re-impregnated (0.4  g deltamethrin, 
K–O TAB, Aventis) before the beginning of the rainy sea-
son and re-impregnation coverage was always over 95 % 
[46]. This could partly explain the associations between 
ITN exposure and headache/dizziness in mothers.
This study has strengths and limitations. With regard 
to its strengths it has to be considered that it is nested 
into a large randomized controlled trial, making bias 
less likely. With regard to potential limitations it should 
be considered that the data on potential side effects are 
mainly based on self-reports in a rather limited sample 
size. While significant differences may well have occurred 
by chance, more rare differences in the occurrence of side 
effects may have been missed due to lack of power. More-
over it is possible that it may not be culturally acceptable 
to honestly report adverse effects of a product which has 
been free of charge which may underestimate potential 
side effects of the insecticide [37]. Finally, the follow up 
period was only 18 weeks which makes the detection of 
long-term effects impossible.
Conclusions
The study provides further evidence for ITNs being 
rather safe in children and even in newborns. Given the 
high impact of ITNs on malaria burden in endemic areas, 
these findings further support an unrestricted use of 
ITNs for malaria prevention.
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